๐
Inlyta
axitinib
Carcinoma, Renal Cell
โ
Authorised
โ
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
โ ๏ธ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta